ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Director of Direct-to-Consumer Marketing at electroCore, commented, "Using Truvaga Plus with the Apple Health app on the iPhone empowers you to better manage your hea

ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 7, 4:30 PM ESTDial-In: (646) 931-3860Webinar ID: 885 4355 1292 Passcode: 419231Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc.electroCore, Inc. and its subsidiaries ("electroCore

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented his study entitled, "Adjunctive Non-Invasive Vagus Nerve Stimulation Helps Reduce Symptoms of Mild Traumatic Brain Injury," on March 22, 2025, demonstrating significant symptom relief when using nVNS in patients suffer

ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore's investor relations at [email protected]. About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectron

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of "The Americas' Fastest Growing Companies 2025." Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors. This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the years 2020 and 2023. The healthcare & life sciences sector represented 10% of the of the fastest-growing companies. electroCore ranked 16 out of the other 29 healthcare & life sciences companies m

ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025. Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day. DATE: April 10, 2025TIME: 2:15 p.m. ETWEBCAST: electroCore Group Presentation A live audio webcast and replay of the presentation will be available using the above dedicated link. Investors attending the conference who are interested in schedul

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. "Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veterans," commented Dan Goldberger, Chief Executive Officer of electroCore. "VA Hospital revenue accelerated in February and March, after modest slowing in

Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

8-K - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

S-8 - electroCore, Inc. (0001560258) (Filer)

10-K - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

S-3/A - electroCore, Inc. (0001560258) (Filer)

S-3 - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

8-K - electroCore, Inc. (0001560258) (Filer)

**Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond

ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting.   "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo

Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million, compares favorably to previously announced guidance of $4M December 31, 2020 cash and cash equivalents of $22.6M BASKING RIDGE, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the fourth quarter. “Notwithstanding the resurgence of COVID-19 case counts which began midway through the fourth qu

SC 13D/A - electroCore, Inc. (0001560258) (Subject)

SC 13G/A - electroCore, Inc. (0001560258) (Subject)

SC 13D - electroCore, Inc. (0001560258) (Subject)

SC 13G - electroCore, Inc. (0001560258) (Subject)

SC 13G/A - electroCore, Inc. (0001560258) (Subject)

SC 13G/A - electroCore, Inc. (0001560258) (Subject)

SC 13G - electroCore, Inc. (0001560258) (Subject)

SC 13G/A - electroCore, Inc. (0001560258) (Subject)

SC 13G - electroCore, Inc. (0001560258) (Subject)

Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), including its Quell platform, positioning itself as a diversified, commercial-scale player in non-invasive health and wellness treatments. NURO is a commercial stage h

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 45% over third quarter 2023Year to date, revenue of $18.1 million; an increase of 67% over the first nine months of 2023Sales of Rx gammaCore™ and Truvaga™ before variable TAC-STIM™ sa

ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024, after the close of the market on Wednesday, November 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 13, 4:30 PM ESTDial-In:  877-407-8835 / +1 201-689-8779Conference ID: 13744121Webcast:  electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improv

LONDON, UNITED KINGDOM / ACCESSWIRE / September 4, 2024 / Ecora Resources PLC (LSE/TSX:ECOR) announces half year results for the six months ended 30 June 2024 which are available on both the Group's website at www.ecora-resources.com and on SEDAR at www.sedar.com. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future. The Group has a portfolio which combines volume growth in 2024 and 2025 from its currently producing royalty portfolio with an extensive pipeline of high-quality development projects that are expected to drive material medium term revenue growth.Marc Bishop Lafleche, Chief Executive Officer of

ROCKAWAY, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024, after the close of the market on Wednesday, August 7, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, August 7, 4:30 PM EDTDial-In: 877-407-8835 / +1 201-689-8779Conference ID: 13744119Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced first quarter 2024 financial results. Recent Highlights Record revenue of $5.4 million, an increase of 96% over first quarter 2023Launched our direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus™ First Quarter 2024 Financial Results For the quarter ended March 31, 2024, electroCore reported net sales of $5.4 million c

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: located hereConference ID: 13744118Webcast:  electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving heal

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13744117Webcast: electroCore Earnings Webcast About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicat

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)

4 - electroCore, Inc. (0001560258) (Issuer)